NASDAQ:IVVD Invivyd (IVVD) Stock Price, News & Analysis $0.67 -0.05 (-6.64%) Closing price 04:00 PM EasternExtended Trading$0.68 +0.01 (+1.00%) As of 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Invivyd Stock (NASDAQ:IVVD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Invivyd alerts:Sign Up Key Stats Today's Range$0.66▼$0.7250-Day Range$0.55▼$1.0252-Week Range$0.53▼$3.07Volume2.78 million shsAverage Volume4.06 million shsMarket Capitalization$198.46 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingHold Company Overview Invivyd, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based medicines designed to prevent and treat viral diseases. The company’s approach is intended to provide durable protection against rapidly evolving viruses by using engineered monoclonal antibodies that can be updated as pathogens change. Invivyd’s leading product is pemivibart, marketed in the United States under the brand name PEMGARDA. The product received emergency use authorization from the U.S. Food and Drug Administration for pre-exposure prophylaxis against COVID-19 in certain moderately to severely immunocompromised individuals for whom vaccination is not expected to provide adequate protection. Invivyd is also advancing additional antibody candidates for infectious disease indications. The company was founded as Adagio Therapeutics and changed its name to Invivyd in 2023. Based in Waltham, Massachusetts, Invivyd conducts research and clinical development activities intended to support the availability of its antibody therapies in the United States and other markets. The company is led by Mark J. Esser, Ph.D., who serves as president and chief executive officer.AI Generated. May Contain Errors. Read More Invivyd Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreIVVD MarketRank™: Invivyd scored higher than 69% of companies evaluated by MarketBeat, and ranked 194th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingInvivyd has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialInvivyd has a consensus price target of $10.00, representing about 1,388.1% upside from its current price of $0.67.Amount of Analyst CoverageInvivyd has only been the subject of 4 research reports in the past 90 days.Read more about Invivyd's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Invivyd are expected to grow in the coming year, from ($0.51) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Invivyd is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Invivyd is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInvivyd has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Invivyd's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.09% of the float of Invivyd has been sold short.Short Interest Ratio / Days to CoverInvivyd has a short interest ratio ("days to cover") of 3.58, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Invivyd has recently increased by 10.81%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInvivyd does not currently pay a dividend.Dividend GrowthInvivyd does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.56 News SentimentInvivyd has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Invivyd this week, compared to 4 articles on an average week.Search Interest26 people have searched for IVVD on MarketBeat in the last 30 days. This is an increase of 160% compared to the previous 30 days.MarketBeat Follows14 people have added Invivyd to their MarketBeat watchlist in the last 30 days. This is an increase of 367% compared to the previous 30 days. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Invivyd insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $176,540.00 in company stock.Percentage Held by Insiders12.25% of the stock of Invivyd is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.36% of the stock of Invivyd is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Invivyd's insider trading history. Receive IVVD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invivyd and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IVVD Stock News HeadlinesArcus Biosciences (NYSE:RCUS) versus Invivyd (NASDAQ:IVVD) Head to Head ReviewOctober 12 at 8:14 AM | americanbankingnews.comBTIG Sticks to Its Buy Rating for Invivyd (IVVD)October 5, 2026 | theglobeandmail.comHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.October 12 at 1:00 AM | Banyan Hill Publishing (Ad)Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 5, 2026 | globenewswire.comInvivyd, Inc. Announces Positive Topline Results from Liberty Phase 3 Study Demonstrating Vyd2311 Safety and Tolerability Superior to Mrna-Based Covid-19 VaccineSeptember 30, 2026 | marketscreener.comMInvivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 VaccineSeptember 30, 2026 | marketscreener.comMInvivyd's VYD2311 Meets Primary Goals in Head-to-Head mRNA Vaccine TrialSeptember 29, 2026 | finance.yahoo.com3 Small-Cap Biotechs With Binary Catalysts on the Calendar (IVVD)Kodiak Sciences, Capricor Therapeutics and Invivyd each face pivotal clinical trial or FDA decisions before the end of 2026 that could significantly move their stock prices.September 13, 2026 | marketbeat.comSee More Headlines IVVD Stock Analysis - Frequently Asked Questions How have IVVD shares performed this year? Invivyd's stock was trading at $2.47 on January 1st, 2026. Since then, IVVD shares have decreased by 72.8% and is now trading at $0.6720. How were Invivyd's earnings last quarter? Invivyd, Inc. (NASDAQ:IVVD) posted its quarterly earnings results on Thursday, August, 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.03. The firm had revenue of $14.29 million for the quarter, compared to analysts' expectations of $14.40 million. Invivyd had a negative trailing twelve-month return on equity of 59.73% and a negative net margin of 183.90%. When did Invivyd IPO? Invivyd (IVVD) raised $309 million in an initial public offering (IPO) on Friday, August 6th 2021. The company issued 18,200,000 shares at a price of $16.00-$18.00 per share. How do I buy shares of Invivyd? Shares of IVVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Invivyd own? Based on aggregate information from My MarketBeat watchlists, some other companies that Invivyd investors own include American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), AUO (AUOTY), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings8/13/2026Today10/12/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (5m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 IVVD's financial health is in the Yellow zone, according to TradeSmith. IVVD has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IVVD CIK1832038 Webwww.invivyd.com Phone781-819-0080FaxN/AEmployees122Year FoundedN/APrice Target and Rating Average Price Target for Invivyd$10.00 High Price Target$10.00 Low Price Target$10.00 Potential Upside/Downside+1,381.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$52.49 million Net Margins-183.90% Pretax Margin-183.90% Return on Equity-59.73% Return on Assets-48.97% Debt Debt-to-Equity RatioN/A Current Ratio5.87 Quick Ratio5.87 Sales & Book Value Annual Sales$53.43 million Price / Sales3.72 Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book0.65Miscellaneous Outstanding Shares294,760,000Free Float258,651,000Market Cap$198.96 million OptionableOptionable Beta0.95 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:IVVD) was last updated on 10/12/2026 by MarketBeat.com Staff. From Our PartnersPalantir and Wall Street are in on it…Palantir just signed a major AI deal with a company most investors have never heard of. Wall Street has pou...Monument Traders Alliance | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredTrump To Relaunch USD?President Trump's summit with Xi Jinping drew headlines for tariffs and trade truces, but the real story may b...Porter & Company | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe AI Stock to Keep an Eye on Before Election Day (See Why)In 2019, Charles Mizrahi named Marvell Technology his top AI pick. It's since climbed 1300 percent. Now he'...Prosperity Research | SponsoredThis little-known gold fund distributes cash every FridayGold pays no dividends, no interest, no yield - it just sits there. Yet investors are reportedly collecting up...Investors Alley | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invivyd With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
